ClinicalTrials.gg
CompletedNCT06494397Updated Sep 19, 2025

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

A Phase 1 interventional study of VHX-896 and iloperidone and Iloperidone and VHX-896 in Schizophrenia and Bipolar I Disorder, sponsored by Vanda Pharmaceuticals. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.

Enrollment
10th of 11
26 · median 260
Started
2024
the only one that year
Phase 1
3 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
7 of 11
Vanda Pharmaceuticals

Among the 11 studies testing iloperidone in Schizophrenia, this one is the 10th largest by enrollment, is the only one that started in 2024, is one of 3 in phase 1, and was the 11th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About iloperidone

iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing iloperidone in Schizophrenia, or all of them as a file.
02

Study summary

Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state conditions.

03

Conditions studied

  • Schizophrenia
  • Bipolar I Disorder

Browse trials for

Keywords

  • Iloperidone
  • VHX-896
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 18 to 65 years of age (inclusive)
  • Diagnosed with either schizophrenia or bipolar I disorder, manic or mixed type, according to the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition, Text Revision ()
  • Patients must be symptomatically stable and on a stable treatment with an oral atypical antipsychotic at an adequate dose (3 months prior to enrollment) and not suffer from acute increase of their psychosis or be hospitalized within the past 2 months

Exclusion criteria

Exclusion Criteria:

  • History of to any of the study drugs or to drugs of similar chemical classes
  • Cytochrome P450 2D6 (CYP2D6) poor metabolizers and use of prescription medication or OTC medication that strongly inhibits CYP2D6 or or induces CYP3A4 within 5 half-lives of baseline
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Sequence A: VHX-896 then iloperidone

    Drug: VHX-896 and iloperidone

  • Experimental
    Sequence B: Iloperidone then VHX-896

    Drug: Iloperidone and VHX-896

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence between VHX-896 tablets relative to iloperidone tablets

    As measured by plasma concentrations

    Time frame: 12 hours

Secondary outcomes

  1. Assessment of safety and tolerability of VHX-896 and iloperidone

    As measured by spontaneous reporting of adverse events (AEs).

    Time frame: 24 days

07

Study locations

3 sites
  • Vanda Investigational Site
    Los Alamitos, California 90720, United States
  • Vanda Investigational Site
    Gaithersburg, Maryland 20877, United States
  • Vanda Investigational Site
    Marlton, New Jersey 08053, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Oct 2024, 3 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 10, 2024
StartActual
Jul 11, 2024
Primary completionActual
Oct 24, 2024
CompletionActual
Oct 24, 2024
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06494397
Responsible party
Sponsor
First posted
Jul 10, 2024
Start date
Jul 11, 2024
Primary completion
Oct 24, 2024
Completion
Oct 24, 2024
Last update
Sep 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Milsaperidone · Iloperidone

Start the discussion